Today after the close the following companies are scheduled to report earnings: ANY.
Futures are modestly lower after hours: S&P 500 futures are -0.25% from fair value of 2,365 and Nasdaq100 futures are -0.88 from the fair value of 5,441.
Tomorrow morning, economic reports scheduled to be released include: Trade Balance (08:30 ET; consensus -$44.7 billion).
Tomorrow before the open the following companies are scheduled to report earnings: CONN, AYI, ISCA.
In other news, Paratek Pharma (PRTK) reports 'positive' Phase 3 study of Omadacycline in community-acquired bacterial pneumonia; will host a webcast and conference call for investors at 4:30 pm ET today.
The global, pivotal Phase 3 clinical study known as OPTIC (Omadacycline for Pneumonia Treatment in the Community), compared the safety and efficacy of once-daily, IV-to-oral omadacycline to IV-to-oral moxifloxacin for treating adults with CABP. In the study, 774 patients were randomized. Omadacycline met the FDA-specified primary endpoint of statistical non-inferiority (NI) in the intent-to-treat (ITT) population (10% NI margin, 95% confidence interval) compared to moxifloxacin at the early clinical response (ECR) 72-120 hours after initiation of therapy. The ECR rates for the omadacycline and moxifloxacin treatment arms were 81.1 % and 82.7%, respectively.
Additionally, the FDA-specified secondary endpoints evaluated omadacycline at the post treatment evaluation (PTE) visit 5-10 days after the completion of therapy in both the ITT population (87.6% for omadacycline vs. 85.1% for moxifloxacin) and in the clinically evaluable (CE) population (92.9% for omadacycline vs. 90.4% for moxifloxacin) as determined by investigators. The secondary endpoints also achieved statistical non-inferiority.